Toggle light / dark theme

Unlimited Technology Systems breach impacts 3.8 million people

Healthcare software company Unlimited Technology Systems reported that more than 3.8 million people were impacted by a data breach incident that occurred in October 2025.

The organization submitted data breach notification samples to the authorities this year on July 1st without revealing the exact number of impacted individuals.

An entry on the breach notification portal of the U.S. Dept. of Health and Human Services now shows that a company server was breached and data of 3,803,750 people was exposed to an unauthorized party.

Drug temporarily reverses autism-like brain changes in adult mice within hours

A new mouse study led by UCLA Health suggests that inflammation during pregnancy can trigger autism-like changes in offspring, but those brain and behavioral effects may be rapidly, though temporarily, reversible in adulthood with a single dose of the immunosuppressive drug rapamycin.

Even mild inflammation during midpregnancy has been shown to result in autism-like symptoms in offspring, abnormal brain growth, seizures and heightened sensitivity to everyday sensory input that persist into adulthood.

In the study published in the journal Nature Communications, UCLA researchers found that a single dose of rapamycin significantly improved brain signaling and behavioral symptoms in these offspring within about two hours, too short a time to correct underlying physical brain changes caused by maternal inflammation.

The impact of artificial sweeteners on bacterial physiology and the microbiome

Artificial sweeteners are non-nutritive compounds that have a profound sweetening effect with a negligible to zero calorific contribution. Global initiatives to reduce sugar consumption to tackle health conditions such as obesity have led to a significant increase in their consumption in recent decades. Artificial sweeteners have undergone extensive testing to determine whether their consumption could impact human health; however, their impact on the microbiome and microbial physiology has been comparatively overlooked. Recent work has demonstrated that artificial sweeteners (e.g., Ace-K, saccharin, and aspartame) can influence the oral and gut microbiome and that they can significantly affect bacterial behavior and growth. In this review, we will contextualize these findings and explore their relevance to human artificial sweetener consumption.

GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds

GLP-1 drugs such as Ozempic have transformed healthcare in recent years, dramatically altering how we treat conditions like type 2 diabetes and obesity.

But while the medications are primarily used to help lower blood sugar and reduce appetite, scientists keep finding GLP-1 effects appear to extend much further, affecting our health in ways we never expected.

Now, a new study has uncovered another unintended effect, and it shows we’re still only scratching the surface of fully understanding how GLP-1 receptor agonists impact the body.

Self-repairing, recyclable substrate developed for durable soft sensors

Soft sensors convert movement, temperature and moisture into electrical signals. Repeated bending and friction can cause their metal conductors to peel from the underlying polymer, while physical damage, such as cuts, can disable the device. Commonly used petroleum-derived substrates are also environmentally unfriendly because they are difficult to recycle.

Researchers at the College of Design and Engineering at the National University of Singapore (NUS CDE) have developed a soft, stretchable substrate that repairs itself, firmly grips metal conductors and can be remolded or broken down after use. It could make wearable patches and electronic skin used in applications such as health monitoring and virtual reality more durable while enabling the recovery of valuable components, thus reducing electronic waste.

The new material, called an intrinsically dynamic biosubstrate (IDBS), was developed by researchers led by assistant professor Zhai Wei from the Department of Mechanical Engineering at NUS CDE. Their findings were published in Nature Sustainability on June 19, 2026.

Restoring Saliva Flow May Improve Oral Health in Down Syndrome

However, Carpenter was not entirely convinced that hyposalivation drives periodontitis. “I don’t think there’s much evidence for that in…literature about human studies,” he said. Instead, he said that inflammation—which is present in Dp16 salivary glands—could cause hyposalivation. “There’s lots of literature that shows that inflammatory cells can affect salivary secretion,” he noted.

According to Yule, next steps could include looking at whether dysregulated calcium signaling—which is linked with several other diseases—also underlies other Down syndrome-related complications like Alzheimer’s disease. While drugs targeting calcium signaling could potentially help, there is a complexity to it, he noted. “Knowing what the target is [is] good, but the fact that the target is almost universal in cells, then that makes you think about whether it’s something that could be targeted,” explained Yule.

Lacruz agreed that disrupted calcium signaling occurs in other tissues as well. “Understanding why calcium is dysregulated is an important part of what we need to do [next],” he said. More work needs to be done to translate the findings to the clinic, “but we see that as a way forward to potentially impacting the lives of individuals with Down syndrome,” said Lacruz.

JCI: Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

2 School of Medicine, Chang Gung University and Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

3Imperial Lupus Centre, Imperial College Healthcare NHS Trust, London, United Kingdom.

Comorbidities and Outcomes in People with Functional Neurological Disorder

In this cohort study, we retrospectively analyzed a large FND cohort using TriNetX, a federated health research platform aggregating electronic health records from approximately 160 million individuals across 143 health care organizations in 17 countries. Diagnoses follow standardized clinical coding. Reporting adhered to the STROBE guideline. This study was exempt from IRB review and informed consent given the use of deidentified data, according to the Common Rule (45 CFR §46) and UK regulations from the Health Research Authority.

Demographics and lifetime comorbidities were extracted for patients with an initial F44.4-F44.7 diagnosis between 1995 and 2024. Clinical outcomes were compared between matched cohorts with an initial diagnosis between 2015 and 2024 to reflect contemporary care for all FND vs multiple sclerosis (MS; G35), FND-motor vs MS, and FND-seizure vs epilepsy (G40), controlling for age, sex, race, and ethnicity via propensity score matching, testing 2-sided z tests on absolute risk differences at a significance level of P .05 after Bonferroni correction for multiple comparisons, and calculating odds ratios with 95% CIs. Data extraction and analyses were performed in April 2025 on the web-based interface TriNetX LIVE. Full methods are described in eMethods 1 to 3 in Supplement 1.